Gain Therapeutics (GANX) Assets (2020 - 2025)
Historic Assets for Gain Therapeutics (GANX) over the last 6 years, with Q3 2025 value amounting to $11.0 million.
- Gain Therapeutics' Assets fell 2362.57% to $11.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $11.0 million, marking a year-over-year decrease of 2362.57%. This contributed to the annual value of $12.1 million for FY2024, which is 3485.05% down from last year.
- Per Gain Therapeutics' latest filing, its Assets stood at $11.0 million for Q3 2025, which was down 2362.57% from $9.8 million recorded in Q2 2025.
- Gain Therapeutics' Assets' 5-year high stood at $48.0 million during Q1 2021, with a 5-year trough of $9.8 million in Q2 2025.
- Over the past 5 years, Gain Therapeutics' median Assets value was $19.2 million (recorded in 2024), while the average stood at $24.3 million.
- Per our database at Business Quant, Gain Therapeutics' Assets soared by 30591.02% in 2021 and then plummeted by 5023.08% in 2023.
- Quarter analysis of 5 years shows Gain Therapeutics' Assets stood at $39.0 million in 2021, then tumbled by 38.18% to $24.1 million in 2022, then fell by 22.78% to $18.6 million in 2023, then plummeted by 34.85% to $12.1 million in 2024, then dropped by 9.5% to $11.0 million in 2025.
- Its Assets was $11.0 million in Q3 2025, compared to $9.8 million in Q2 2025 and $11.6 million in Q1 2025.